<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842878</url>
  </required_header>
  <id_info>
    <org_study_id>GNT-015-FKRP</org_study_id>
    <nct_id>NCT03842878</nct_id>
  </id_info>
  <brief_title>Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I</brief_title>
  <official_title>Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Limb-Girdle Muscular Dystrophy 2I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, longitudinal, interventional, single-group, multicenter natural history study to
      better know the LGMD2I disease physiopathology. The duration of participation for each
      patient will be up to 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration Duration from First visit of first patient (FPFV) to Last visit of last
      patient (LPLV) : 3 years

      Study objectives Primary objective:

      To characterize the disease course in Limb-Girdle Muscular Dystrophy 2I (LGMD2I) patients
      using standardized and disease appropriate evaluations.

      Secondary objectives:

      To identify clinical, imaging and/or laboratory parameters that are indicators of the disease
      course in LGMD2I To identify the best outcome measure for further therapeutics approaches
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6-Minute Walk Test</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10-Meter Walk test (10MWT)</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Timed Up and Go (TUG) test</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Four-stair climb test</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>North Star Assessment for Neuromuscular Disorders (NSAD)</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Scale to assess patient's abilities necessary to remain functionnaly ambulant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper limb assessment via the Performance of the Upper Limb (PUL) tool version 2.0</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recording of aids for ambulation</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Isokinetic muscle testing using the Biodex System (optional)</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary function test</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Presence of cardiac abnormalities or any ventricular extrasystoles will be investigated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Cardiac dimensions will be measured to investigate the presence of any dilated cardiomyopathy</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>LGMD2I</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female and male patients ≥ 16 years old
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female and male patients

          2. Patients ≥ 16 years old

          3. Clinical diagnosis of LGMD2I and gene testing demonstrating two pathogenic mutations
             in fukutin-related protein gene, FKRP)

          4. Ambulant patients

        Exclusion Criteria:

        1. Patients presenting other disease which may significantly interfere with the
        interpretation of LGMD2I natural history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Vissing, PR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Vissing, PR</last_name>
    <phone>+45 35452562</phone>
    <phone_ext>1842</phone_ext>
    <email>john.vissing@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pr John Vissing</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Vissing, Pr</last_name>
      <phone>+45 35452562</phone>
      <email>john.vissing@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Tanya Stojkovic</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Stojkovic, Dr</last_name>
      <phone>+33 (0) 1 42 16 37 76</phone>
      <email>stojkovic.tanya@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pr Volker Straub</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker Straub, Pr</last_name>
      <phone>+44 (0) 191 241 8655</phone>
      <email>volker.straub@newcastle.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophies, Limb-Girdle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

